A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Inclusion Criteria: * Willing and able to provide written informed consent. * Male or female aged ≥18 years at the time of signing the informed consent. * Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study: * Head and neck cancer * Cervical cancer * Non-small cell lung cancer * HPV positive anogenital cancers * Sarcoma * Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate. * Willing to provide a buccal swab for HLA testing * Willing to provide a saliva sample to use as a normal control for the LOH assay * Have access to an adequate FFPE tumor block that is \<8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team. Exclusion Criteria: • Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.